In this podcast Dr. Harry Cridge, an ACVIM and ECVIM board-certified specialist in small animal internal medicine, will discuss his approach to the management of pancreatitis in dogs. This podcast will include discussion of Panoquell®-CA1, a novel and innovative solution for neutrophilic inflammation in acute pancreatitis. Dr. Cridge is an ACVIM and ECVIM board-certified internal medicine specialist with clinical and research interests in disorders of the exocrine pancreas. He is 1 of 3 RCVS recognized specialist in Small Animal Medicine (Gastroenterology) worldwide. Dr. Cridge obtained his veterinary medical degree from University College Dublin, before moving to the United States to pursue an internship and small animal internal medicine residency at Mississippi State University. Following residency, he joined the faculty at Michigan State University where he is an Associate Professor. He has published in multiple prestigious journals and textbooks. PANOQUELL®-CA1 (fuzapladib sodium for injection) PANOQUELL® is a registered trademark of Ishihara Sangyo Kaisha, Ltd. © 2023 Ceva Animal Health, LLC PANOQUELL®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141 to 567. It is a violation of federal law to use this product other than as directed in the labeling. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. *IMPORTANT SAFETY INFORMATION: The safe use of PANOQUELL®-CA1 has not been evaluated in dogs with cardiac disease, hepatic failure, or renal impairment; dogs that are pregnant, lactating, or intended for breeding; or puppies under 6 months of age. PANOQUELL®-CA1 should not be used in dogs with a known hypersensitivity to fuzapladib sodium. PANOQUELL®-CA1 is a highly protein-bound drug and its use with other highly protein-bound medications has not been studied. The most common adverse effects in the pilot field study were anorexia, digestive tract disorders, respiratory tract disorders, and jaundice. PANOQUELL®-CA1 is not for use in humans. Limited data is available on the potential teratogenic effects of fuzapladib sodium. Therefore, anyone who is pregnant, breastfeeding, or planning to become pregnant should avoid direct contact with PANOQUELL®-CA1. For additional information on the use of PANOQUELL®-CA1, please refer to the package insert. See prescribing and product information: https://www.panoquell.com/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related